Working… Menu

Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer (PACT-12)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00967603
Recruitment Status : Completed
First Posted : August 28, 2009
Last Update Posted : February 1, 2012
Information provided by (Responsible Party):
Michele Reni, IRCCS San Raffaele

Brief Summary:

RATIONALE: Sunitinib malate may stop the growth of tumor cells by blocking some of the tyrosine kinases needed for angiogenesis and cell growth. It is not yet known whether sunitinib malate is effective as maintenance therapy in delaying tumor progression in patients with metastatic pancreatic cancer who are progression-free after 6 months of induction chemotherapy.

PURPOSE: This randomized phase II trial is studying sunitinib malate as maintenance therapy to see how well it works compared with observation in avoiding tumor progression after induction chemotherapy in patients with metastatic pancreatic cancer.

Condition or disease Intervention/treatment Phase
Pancreatic Cancer Drug: sunitinib Phase 2

Detailed Description:


  • Compare the 6-month progression-free survival of patients with metastatic pancreatic cancer without progression after 6 months of induction chemotherapy treated with sunitinib malate as maintenance therapy vs observation.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms:

  • Arm I: Patients receive oral sunitinib malate once daily for up to 6 months in the absence of disease progression or unacceptable toxicity.
  • Arm II: Patients undergo observation only.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Maintenance Therapy With Sunitinib or Observation in Metastatic Pancreatic Cancer: a Phase II Randomized Trial.
Study Start Date : February 2008
Actual Primary Completion Date : January 2012
Actual Study Completion Date : January 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
No Intervention: observation
no therapy until progression
Experimental: sunitinib
sunitinib until progression or for a maximum of 6 months
Drug: sunitinib
oral sunitinib 37.5 mg daily
Other Name: SUTENT

Primary Outcome Measures :
  1. 6-month progression-free survival [ Time Frame: every 2 months during therapy; every 3 months thereafter ]
    CT scan

Secondary Outcome Measures :
  1. Response rate [ Time Frame: every 2 months during therapy; every 3 months thereafter ]
    CT scan

  2. Toxicity [ Time Frame: monthly during therapy ]
    outpatient visit

  3. OVERALL SURVIVAL [ Time Frame: monthly ]
    outpatient visit

  4. PROGRESSION-FREE SURVIVAL [ Time Frame: every 2 months during therapy; every 3 months thereafter ]
    CT scan

  5. endothelial circulating cells [ Time Frame: baseline + every 2 months during therapy until progression ]
  6. pharmacogenomics [ Time Frame: baseline ]
  7. pharmacokynetics [ Time Frame: after 2 months of therapy ]
  8. pharmacodynamics [ Time Frame: baseline and every 2 months until progression ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Pathologically confirmed metastatic pancreatic adenocarcinoma

    • Stage IV disease
  • Received chemotherapy for a duration of 6 months
  • No progressive disease for ≥ 6 months since beginning of induction chemotherapy (irrespective of regimen and response: stable disease, partial response, or complete response) demonstrated by the following:

    • Two consecutive CT or MR scans separated by ≥ 6 weeks
    • Normal or no CA19.9 increase > 20% during the last month


  • Karnofsky Performance Status 50-100%
  • Adequate bone marrow, liver, and kidney function
  • Normal thyroid gland function (euthyroid)
  • Not pregnant or nursing
  • No duodenal, gastric, or intestinal infiltration
  • Able to take oral medication
  • None of the following conditions related to cardiac disease, failure, or vascular disease including any of the following:

    • QTc interval prolongation
    • Congestive heart failure
    • Serious cardiac arrhythmias
    • Active coronary artery disease
    • Myocardial infarction
    • Ischemia
    • Cerebrovascular accident
    • Evidence of pre-existing uncontrolled hypertension
  • No other malignancies except surgically cured carcinoma in situ of the cervix, basal or squamous cell carcinoma of the skin, or other adequately treated neoplasms for which the patient has been disease-free for ≥ 5 years


  • See Disease Characteristics
  • No other prior chemotherapy apart from first-line treatment for pancreatic cancer
  • More than 3 weeks and less than 8 weeks since prior chemotherapy (> 1 week in the case of fluorouracil as continuous infusion or capecitabine)
  • No prior antiangiogenesis drugs, including any of the following:

    • Sunitinib malate
    • Sorafenib
    • Bevacizumab
    • AZD2171
    • Vatalanib
    • VEGF trap
    • Pazopanib
  • More than 1 month since prior major surgical procedure and completely recovered
  • More than 7-12 days since prior and no concurrent drugs that are known CYP3A4 inhibitors
  • No concurrent drugs with potential anti-arrhythmic activity
  • No concurrent thrombolytic agent at therapeutical dose
  • No concurrent treatment with other experimental drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00967603

Layout table for location information
San Raffaele Scientific Institute
Milan, Italy, 20132
Sponsors and Collaborators
IRCCS San Raffaele
Layout table for investigator information
Principal Investigator: Michele Reni, MD Istituto Scientifico H. San Raffaele

Layout table for additonal information
Responsible Party: Michele Reni, MD, IRCCS San Raffaele Identifier: NCT00967603     History of Changes
Other Study ID Numbers: CDR0000643632
PACT-12 ( Other Identifier: IRCCS San Raffaele )
2008-000814-65 ( EudraCT Number )
First Posted: August 28, 2009    Key Record Dates
Last Update Posted: February 1, 2012
Last Verified: December 2009
Keywords provided by Michele Reni, IRCCS San Raffaele:
adenocarcinoma of the pancreas
stage IV pancreatic cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Pancreatic Diseases
Digestive System Diseases
Endocrine System Diseases
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action